Saurabh Kumar* Pages 940 - 942 ( 3 )
Background: Novel Coronavirus (COVID-19), respiratory diseases and a major threat to mankind is spreading at an unstoppable rate affecting almost every part of the world with Europe being the most affected continent. Originated from China in December 2019 with sequence homology similar to SARS having a high rate of mutation has created a global pandemic with no effective therapy available.
Objective: This editorial summarizes the list of potential antiviral drugs or other effective therapy that is in the clinical trial.
Methods: The literature search is based on recent publications (year, 2020) available on PubMed and drug/therapy registered on the ClinicalTrial.gov portal.
Results: Hydroxychloroquine, tocilizumab, lopinavir/ritonavir, remdesivir, and convalescent plasma are some of the most common drug/therapy that has come as a hope against COVID-19.
Conclusion: In view of the current COVID-19 situation, more rigorous efforts are needed. Drugs with better outcomes need more exploration.
COVID-19, pandemic, hydroxychloroquine, antiviral, clinical trial, drugs.
Young Policy Professional, DST-Centre for Policy Research, Indian Institute of Science (IISc)